您的购物车当前为空
MGH-CP1 是 TEAD2 (IC50:710 nM) 及 TEAD4 (IC50:672 nM) 自棕榈酰化抑制剂,口服有活性,可降低细胞内源性或异位表达的 TEAD 蛋白棕榈酰化水平。MGH-CP1 与 Lats1/2 缺失,是 Myc 的表达受到抑制,阻碍上皮细胞过度增殖,诱导细胞凋亡。


为众多的药物研发团队赋能,
让新药发现更简单!
MGH-CP1 是 TEAD2 (IC50:710 nM) 及 TEAD4 (IC50:672 nM) 自棕榈酰化抑制剂,口服有活性,可降低细胞内源性或异位表达的 TEAD 蛋白棕榈酰化水平。MGH-CP1 与 Lats1/2 缺失,是 Myc 的表达受到抑制,阻碍上皮细胞过度增殖,诱导细胞凋亡。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 262 | In stock | |
| 5 mg | ¥ 578 | In stock | |
| 10 mg | ¥ 892 | In stock | |
| 25 mg | ¥ 1,930 | In stock | |
| 50 mg | ¥ 2,970 | In stock | |
| 100 mg | ¥ 4,380 | In stock | |
| 200 mg | ¥ 6,150 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 469 | In stock |
MGH-CP1 相关产品
| 产品描述 | MGH-CP1 is a potent and selective inhibitor TEAD palmitoylation. It exhibits dose-dependent and potent inhibition of TEAD2/4 auto-palmitoylation in vitro with IC50 of 710 nM and 672 nM, respectively. |
| 靶点活性 | TEAD2:672 nM, TEAD4:710 nM |
| 体外活性 | MGH-CP1 exhibits dose-dependent and potent inhibition of TEAD2/4 auto-palmitoylation in vitro, with IC50 of 710 nM and 672 nM, respectively.?Furthermore, ?MGH-CP1 treatment markedly decreased the palmitoylation levels of endogenous or ectopically expressed TEAD proteins in cells. |
| 体内活性 | MGH-CP1 inhibits TEAD activity in Lats1/2 KO intestine in vivo. MGH-CP1 can effectively inhibit the palmitoylation of TEAD proteins in the intestinal epithelium. MGH-CP1 is well tolerated and has no apparent adverse effect on overall animal health or body weight after 2 weeks of treatment. In contrast to its lack of apparent effect in wild-type intestine, MGH-CP1 treatment effectively inhibits upregulation of the TEAD target genes, CTGF and ANKRD1, in Lats1/2 KO intestine |
| 细胞实验 | HEK293T cells, Lats1/2 conditional MEFs and MDA-MB-231 cells were cultured in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin.?For Lats1/2 conditional MEFs carrying CMV-CreER, Lats1/2 was deleted by incubation with 4-OH Tamoxifen (2.5 mM) in DMEM for 4 days prior to further experiment.?Transfection in HEK293T cells was performed using Lipofectamine 2000 (Invitrogen).?For luciferase reporter assays, HEK293T cells were transfected with the luciferase reporter constructs TBS-Luc (8XGTIIC-Luc), Super TOP-FLASH (STF), Gli-BS-Luc, BRE-Luc, and NF-kB-Luc, as well as the expression vectors of pGIPZ-YAP5SA, pGIPZ-YAP6SA, pGIPZ-TAZ4SA, pLV-β-Catenin-ΔN90, pCIG-Wnt3a, pCMV-LRP5C, pCIG-BMP4, pCIG-Gli1,?pGIPZ-IKBKE (Rajurkar et al., 2017) and pCMV-Renilla lucifease.?Luciferase activities were conducted 24 hours after transfection using the dual-luciferase reporter kit (Promega) in the cells treated with or without Wnt3A, LiCl or MGH-CP1.?Assays were conducted in triplicates and quantified using PerkinElmer EnVision plate reader. |
| 分子量 | 368.5 |
| 分子式 | C20H24N4OS |
| CAS No. | 896657-58-2 |
| Smiles | O=C(CSc1ncn[nH]1)Nc1ccc(cc1)C12CC3CC(CC(C3)C1)C2 |
| 密度 | no data available |
| 存储 | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | Ethanol: 74 mg/mL (200.81 mM), Sonication is recommended. DMSO: 45 mg/mL (122.12 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.43 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO/Ethanol
| ||||||||||||||||||||||||||||||||||||
评论内容